Prudential PLC Boosts Position in Kenvue Inc. (NYSE:KVUE)

Prudential PLC lifted its position in Kenvue Inc. (NYSE:KVUE) by 1,699.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 574,143 shares of the company’s stock after purchasing an additional 542,231 shares during the quarter. Prudential PLC’s holdings in Kenvue were worth $12,258,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Kiley Juergens Wealth Management LLC increased its holdings in shares of Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after buying an additional 500 shares during the last quarter. Principle Wealth Partners LLC increased its stake in Kenvue by 3.7% during the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after acquiring an additional 500 shares during the last quarter. White Pine Capital LLC raised its position in Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after purchasing an additional 542 shares during the period. Deseret Mutual Benefit Administrators lifted its stake in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after purchasing an additional 568 shares during the last quarter. Finally, SRS Capital Advisors Inc. grew its holdings in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Down 5.5 %

Kenvue stock opened at $22.33 on Friday. The company has a market capitalization of $42.68 billion, a P/E ratio of 42.14, a PEG ratio of 2.62 and a beta of 1.25. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The stock has a 50-day simple moving average of $22.59 and a 200-day simple moving average of $22.47.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.67%. Kenvue’s payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Canaccord Genuity Group increased their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. UBS Group decreased their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Evercore ISI started coverage on Kenvue in a research note on Monday, March 24th. They set an “in-line” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Kenvue has an average rating of “Hold” and an average target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.